Teva combats generics counterfeiting ring in Europe; AstraZeneca appeal in Seroquel case denied;

 @FiercePharma: ICYMI yesterday: Shunned Gilead/Bristol-Myers hep C combo may be too good for docs to ignore. More | Follow @FiercePharma

> Teva Pharmaceutical Industries ($TEVA) said it's stepping up quality inspections in Europe after discovering counterfeit versions of its omeprazole stomach acid drug, a generic copy of AstraZeneca's ($AZN) Prilosec. Report

> An appeals court upheld the FDA's decision to deny AstraZeneca extended exclusivity for its antipsychotic drug Seroquel. Report

> European regulators backed Roche's ($RHHBY) skin cancer treatment Erivedge and Astellas Pharma's prostate cancer drug Xtandi. Report

> U.K. union leaders are meeting with AstraZeneca executives in a bid to persuade the company not to close an R&D site in Alderley Park and move some 2,000 jobs. Report

> The European Medicines Agency recommended suspending use of all drugs containing tetrazepam, an off-patent anxiety and insomnia treatment, after reports of serious skin reactions. Report

> China's Fosun Pharma has agreed to buy Israeli laser maker Alma Lasers for up to $240 million. Report

Medical Device News

@FierceMedDev: Touch-sensitive robot arm envisioned, in part, as patient care device. Item | Follow @FierceMedDev

@MarkHFierce:  We had a fruitful week at BIO 2013 in Chicago. Check out the highlights. Slideshow | Follow @MarkHFierce

 @DamianFierce: In case you missed it over the weekend, Quintiles finally priced its IPO, seeking $790M. News | Follow @DamianFierce

> Bayer to grab birth control device maker Conceptus for $1.1B. Story

> Judge tosses Smith & Nephew hip lawsuit. More

> RainDance draws Myriad Genetics into $20M Series E. Article

Biotech News

@FierceBiotech: ICYMI: Johnson & Johnson, Evotec bask in Harvard's breaking diabetes discovery. Story | Follow @FierceBiotech

@JohnCFierce: Union wants AstraZeneca to rethink the big Cambridge move, but I don't see it. A reversal would look like schizophrenia. Article | Follow @JohnCFierce

@RyanMFierce: Shunned Gilead/Bristol-Myers hep C combo may be too good for docs to ignore. Story | Follow @RyanMFierce

> U.K. union makes its case against AstraZeneca's R&D relocation. Item

> Giants team on diabetes as Merck partners with Pfizer on SGLT2 combo. News

> Celgene taps biotech Forma for drugs in hot field of protein homeostasis. Article

> Guidelines for contributing an Industry Voices column to Fierce. Publisher's note

CRO News

> AMRI inks 5-year CDMO deal with Ono. Story

> Biocon's CRO now largest in India. Article

> Catalent quadruples biologics capacity with new plant. More

> Icon's revenue soars 26% in Q1. Report

Biotech IT News

> AZ helps NHS develop social media app for U.K. market. More

> Medidata's profit up 51% in Q1 compared to last year as customer base grows. Report

> 'Jeff Bezos of bioinformatics' finds capital and customers for startup. Story

> Treato scores $14.5M VC round, tackles social media analytics for pharma. Article

> Mining clinical notes could detect harmful drug reactions earlier. News

And Finally... The day of the diagnostic dashboard doctor may not be too far off. Report

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.